[CAS NO. 58001-44-8] Clavulanicacid
PRODUCTS SPECIFICATIONS [58001-44-8]
DESCRIPTION [58001-44-8]
Overview
| MDL | MFCD00867004 |
|---|---|
| Molecular Weight | 199.16 |
| Molecular Formula | C8H9NO5 |
| SMILES | O=C([C@@H](/C(O[C@]1([H])C2)=C/CO)N1C2=O)O |
3 Publications Citing Use of MCE
Summary
IC50 & Target
|
β-lactam |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01015417 | Centre Hospitalier Universitaire, Amiens |
Acute Lithiasic Cholecystitis Grade I or II|Symptoms Lasting for Less Than 5 Days|Required Cholecystectomy|Preoperative Amoxicillin Clavulanic Acid for at Most 5 Days
|
May 2010 | Phase 3 |
| NCT02563769 | Temple University|National Institute on Drug Abuse (NIDA)|University of Pennsylvania |
Cocaine Dependence|Cocaine Addiction|Cocaine Abuse|Cocaine-Related Disorders
|
September 2016 | Phase 1 |
| NCT00656747 | Bayer |
Chronic Bronchitis
|
March 2008 | Phase 4 |
| NCT04400110 | IRCCS Burlo Garofolo |
Urinary Tract Infections
|
June 8, 2020 | Phase 4 |
| NCT01096927 | Maggiore Bellaria Hospital, Bologna |
Lower Abdominal Pain|Right Iliac Fossa Pain|Acute Appendicitis
|
January 2010 | Phase 4 |
| NCT00917592 | Consorci Sanitari de Terrassa|Corporacion Parc Tauli |
Diverticulitis
|
December 2005 | Phase 4 |
| NCT00495586 | Catalan Society of Family Medicine|Fondo de Investigacion Sanitaria |
Chronic Obstructive Pulmonary Disease
|
October 2007 | Phase 4 |
| NCT02571959 | Institut de Médecine et d´Epidémiologie Appliquée - Fondation Internationale Léon M´Ba |
Obesity
|
July 24, 2015 | Phase 1|Phase 2 |
| NCT03713424 | University of Missouri-Columbia |
Tobacco Use Disorder
|
March 26, 2019 | Phase 2 |
| NCT04980170 | Jordan University Hospital |
Antibiotics Causing Adverse Effects in Therapeutic Use
|
November 1, 2021 | Early Phase 1 |
| NCT05079620 | UConn Health |
Aspiration|Aspiration Pneumonia
|
November 30, 2021 | Phase 4 |
| NCT00665873 | Universita degli Studi di Catania |
Infections
|
January 2004 | Phase 4 |
| NCT03809312 | CHU de Quebec-Universite Laval |
Chronic Sinus Infection
|
August 14, 2019 | Phase 4 |
| NCT02007603 | Medical University of Vienna |
Infection During Hemodialysis
|
August 2013 | Phase 3 |
| NCT05562349 | Temple University|University of Pennsylvania Perelman School of Medicine|Medical University of South Carolina|Research Foundation for Mental Hygiene, Inc. |
Cocaine Dependence
|
October 2022 | Phase 2 |
| NCT04350502 | Centre Hospitalier Universitaire, Amiens |
Pleural Infection|Empyema|Community-acquired Pneumonia|Pharmacokinetic|Amoxicillin
|
April 4, 2020 | Not Applicable |
| NCT04411914 | Temple University|Beth Israel Deaconess Medical Center|University of Pennsylvania Perelman School of Medicine |
Cocaine Dependence
|
September 1, 2020 | Phase 1 |
| NCT03986762 | Temple University|National Institute on Drug Abuse (NIDA) |
Cocaine Dependence, in Remission|Cocaine Abuse, in Remission|Cocaine-Related Disorders
|
March 12, 2019 | Phase 1 |
| NCT02186951 | University Hospital, Limoges |
Ventilator-associated Pneumonia|Cardiac Arrests With Shockable Rhythm|Mild Therapeutic Hypothermia|Preventive Antibiotics
|
August 18, 2014 | Phase 3 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Solvent & Solubility
H 2 O : 50 mg/mL ( 251.05 mM ; Need ultrasonic)
DMSO : 13.89 mg/mL ( 69.74 mM ; ultrasonic and warming and heat to 60°C)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 5.0211 mL | 25.1054 mL | 50.2109 mL |
| 5 mM | 1.0042 mL | 5.0211 mL | 10.0422 mL |
| 10 mM | 0.5021 mL | 2.5105 mL | 5.0211 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 50 mg/mL (251.05 mM); Clear solution; Need ultrasonic
References
Synonyms